Oxford Biomedica Regulatory News (OXB)

15 Mar 2007 08:42

Oxford Biomedica PLC15 March 2007 Oxford BioMedica PLC Completion of acquisition of Oxxon Therapeutics and issue of shares Oxford, UK - 15 March 2007: Further to the announcement of 12 March 2007, OxfordBioMedica plc (LSE: OXB, 'Oxford BioMedica' or the 'Company') is pleased toannounce that the acquisition of Oxxon Therapeutics Limited ('Oxxon') (the'Acquisition') has now completed. The consideration for the Acquisition wassatisfied by the issue of 27,551,628 new ordinary shares of 1p each in theCompany (with a further 4,219,618 such shares issued to certain Oxxonshareholders in repayment of a loan from them to Oxxon) (together, the'Shares'). The Shares were admitted to the Official List of the UK ListingAuthority and to trading on the London Stock Exchange with effect from 8 a.m.today. In conformity with the FSA's Disclosure and Transparency Rules, we notify themarket that the Company's issued share capital consists of 533,511,200 ordinaryshares of 1p each with voting rights. No shares are held in Treasury. Therefore, the total number of voting rights in Oxford BioMedica is 533,511,200. The above figure may be used by shareholders as the denominator for thecalculation by which they will determine if they are required to notify theirinterest in, or a change of their interest in, Oxford BioMedica under the FSA'sDisclosure and Transparency Rules. -Ends- For further information, please contact: Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000 N M Rothschild & Sons Limited Dr Lynn Drummond Tel: +44 (0)20 7280 5000 City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000 Communications Scientific/Trade Press Enquiries: Gemma Price/ Holly Griffiths/ Katja Stout Tel: +44 (0)20 3008 7550 Northbank Communications N M Rothschild & Sons Limited, which is authorised and regulated by theFinancial Services Authority in the United Kingdom, is acting for OxfordBioMedica and no one else in relation to the Acquisition and will not beresponsible to anyone other than Oxford BioMedica for providing the protectionsafforded to clients of N M Rothschild & Sons Limited nor for providing advice inrelation to the Acquisition or any other matter referred to in thisannouncement. This information is provided by RNS The company news service from the London Stock Exchange